by Christine Sands
Posted in Biopharma
In 2019, the US biosimilar market was worth $737.2 million and continues to grow with a CAGR of 46.2% forecast for 2020-2027, however many are frustrated at the current rate of adoption in the US. But with increasing healthcare costs and a growing debt from Covid-19, what does the next year hold for biosimilar adoption across the US?